Figure 1. Best responses after cediranib monotherapy in recurrent glioblastoma. Initial (left) and best-response (right; in each pair) postgadolinium axial T1-weighted MRI scans from 30 patients. Red outlines, the tumor borders as determined by expert neuroradiologists blinded to patient identity and scan date.